Fc-G-CSF Protein Complex for Neutropenia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic modalities for neutropenia, such as G-CSF, face challenges with stability and efficacy due to denaturation by proteolytic enzymes and reduced titer needed for optimal physiologic effect.
Innovation Solution
A protein complex is formed by linking a physiologically active polypeptide, such as modified human G-CSF, to an immunoglobulin Fc region via a non-peptidyl polymer, specifically site-specifically linked to the N-terminus of the immunoglobulin Fc region.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If G-CSF is chemically attached to PEG to increase blood stability, then blood stability is improved, but the titer needed for optimal physiologic effect is dramatically reduced
Solution Approach 1:
The patent creates a composite protein complex consisting of G-CSF, Fc region, and PEG polymer. This composite structure combines the stability-enhancing properties of PEG with the immunomodulatory properties of the Fc region, while maintaining G-CSF biological activity. The Fc region acts as a bridge that prevents the PEG from interfering with G-CSF's receptor binding, thus preserving titer while achieving blood stability.
Solution Approach 2:
The Fc region serves as an intermediary component between G-CSF and PEG. It mediates the connection in a way that allows PEG to provide stability without directly interfering with G-CSF's active sites. The Fc region's structure enables it to shield the G-CSF-PEG interface from proteolytic enzymes while maintaining the bioactivity of G-CSF.
2Reliability
If G-CSF is administered frequently to maintain blood concentration, then blood concentration is maintained, but patient suffering increases due to excessive administration frequency
Solution Approach 1:
The patent employs partial action by using only the Fc region (rather than a complete antibody) to achieve the desired pharmacokinetic effect. This partial approach is sufficient to extend half-life and maintain stable blood concentrations without requiring excessive dosing frequency, thereby reducing patient burden while maintaining reliability of blood concentration.
Solution Approach 2:
The patent changes the molecular parameters of G-CSF by attaching it to Fc-PEG complex. This parameter change (increased molecular size and altered surface properties) results in extended circulation half-life and reduced clearance rate, allowing maintenance of therapeutic blood concentrations with less frequent administration.
3Stability of the object's composition
If PEG is bound to G-CSF to increase blood stability, then blood stability is improved, but the titer for optimal physiologic effect is dramatically reduced
Solution Approach 1:
The patent segments the stabilizing function from the activity function. PEG is attached to the Fc region rather than directly to G-CSF, creating separate functional domains: the Fc-PEG complex provides stability while the G-CSF portion maintains bioactivity. This segmentation prevents PEG from interfering with G-CSF's titer-dependent physiologic effects.
Solution Approach 2:
The patent applies local quality by placing PEG specifically on the Fc region rather than uniformly on the entire G-CSF molecule. This localized attachment ensures that PEG's stabilizing effect is confined to a specific region, leaving the G-CSF active sites untouched and preserving the titer required for optimal physiologic effect.
Data Source
AI summary
This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.